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clofazimine because its mode of action and resistance are still unclear.
92
In view of the fact that MDT was introduced in the 1980s, and that no information 
113
Each country applied the protocol under their good practices in clinics and ethics.
114
Only aggregated data were collected and analyzed by WHO and authors. Table 1 ). Each country chose one or more 
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9
As shown in Table 2 ).
206
Twenty cases had rifampicin and dapsone resistance, while four cases had ofloxacin 207 and dapsone resistance, but no cases, during this period of collection, were resistant to both 208 rifampicin and ofloxacin or resistant to the three drugs. Cases with resistance to more than 209 one drug were identified in Brazil, India and Indonesia (rifampicin plus dapsone resistance), and new cases, resistance rates were higher in relapses, as in our study [25, 35] . However 223 most reports involved a low number of cases and were not structured over several years.
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224
Additionally, the centers usually did not represent nationwide data and were more research 225 oriented. Resistance to more than one antibiotic has been already observed including 226 resistance to the three drugs we focused on, i.e. dapsone, rifampicin and ofloxacin [10,11].
227
Our data confirmed that such resistance exists at a global level and produced basic 228 resistance rates for the main antileprosy agents.
229
The strengths of this study are (i) that it generated data on AMR in leprosy over a 230 consistent period of time from 19 endemic countries for both new cases and relapses, and
231
(ii) the successful partnership between WHO, national programmes, NGOs and experts 232 laboratories over seven years without much funding. There were some weaknesses, mostly 233 due to organisational and data management issues. In addition, the use of molecular M A N U S C R I P T 
A C C E P T E D
245
It should be noted that we calculated the resistance rates from a very limited
246
proportion of the total new and relapse cases of leprosy reported globally during the 7 years 247 of the study (Supplementary Table 2 ). The lack of a strong information system paired with 
265
This study reveals a potential problem that the leprosy scientific community did not 
275
Countries which reported more than 10 rifampicin-resistance cases were coloured in red,
276
those reporting between 3 to 10 were coloured in yellow and those reporting less than 3 277 cases were reported in green. 
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